Narayana Health (Mazumdar Shaw Medical Centre)
Devi Shetty's low-cost hospital network, whose Mazumdar Shaw cancer centre in Bengaluru applies high-volume, low-price surgery and transplant to cancer and hosts India's second CAR-T developer.
Overview
Narayana Health began in 2001 when cardiac surgeon Devi Shetty founded Narayana Hrudayalaya at Bommasandra outside Bengaluru; it grew into a listed group of 24 hospitals and 7 heart centres across India and the Cayman Islands, known for driving procedure costs down through volume and process. Cancer care is concentrated at the Mazumdar Shaw Medical Centre at Narayana Health City, established in 2009 with Biocon founder Kiran Mazumdar-Shaw as a 1,400-bed cancer and multispecialty campus, with large bone marrow transplant, paediatric haematology-oncology, radiation and surgical programmes. The campus is also home to Immuneel Therapeutics, whose CAR-T Qartemi was developed and trialled there.
- Mazumdar Shaw Medical Centre
- Bone marrow transplant
- Paediatric haematology-oncology
- Low-cost surgical care
The cardiac surgeon who showed that high-volume hospitals can cut the price of complex care by an order of magnitude, a model now applied to cancer at Narayana Health's Bengaluru campus.
Founded Biocon in a garage in 1978 and turned it into the company behind the world's first approved trastuzumab biosimilar, and co-founded a 1,400-bed cancer campus in Bengaluru.
Pages like this
not linked directly; found by shared links- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Most of the world has almost no cancer care, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- InstitutionTata Medical Center, Kolkata
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, Head and neck squamous cell carcinoma.
- CompanyAllotera Therapeutics (formerly Wugen)
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- InstitutionChristian Medical College, Vellore
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, Head and neck squamous cell carcinoma, CAR-T cell therapy.
- InstitutionPeking University People's Hospital
Shares Allogeneic (off-the-shelf) cell therapy, Acute lymphoblastic leukaemia, CAR-T cell therapy.